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Abstract 
The determination of N-methyl pyrrolidine, a potential impurity in the cephalosporin 
antibiotic cefepime, by direct infusion ESI combined with field asymmetric waveform ion 
mobility spectrometry-mass spectrometry (ESI-FAIMS-MS) is demonstrated. The addition of 
a chip-based FAIMS separation prior to detection by time-of-flight mass spectrometry 
enables selective transmission of NMP in the presence of cefepime without interference from 
NMP formed by CID in the mass spectrometer interface. The limits of detection and 
quantification of NMP in cefepime were 0.011% (w/w) and 0.036% (w/w) NMP in cefepime 
respectively, well below the 0.3% (w/w) threshold concentration for NMP in cefepime. The 
% relative standard deviation was 3.9% with linearity for standard additions in the range 
0.005 – 0.5 μg/ml NMP. 
 
Novel Aspect (ToC) 
FAIMS separation prior to mass spectrometry enables selective transmission of NMP in 
cefepime without interference from NMP formed by in-source CID. 
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1. Introduction 
Cefepime (I) is a fourth-generation cephalosporin antibiotic that was developed as a broad 
range activity antibiotic in the 1990s.
1,2
 Cefepime was found to be particularly effective 
against pseudomonas aeruginosa strains which exhibited resistance against other 
cephalosporin antibiotics, such as ceftazidime and cefotaxime.
3
 Cefepime has greater activity 
against Gram-negative bacteria compared to other cephalosporins,
4
 and is used to treat a wide 
degree of infectious diseases.
5
 However, cefepime is unstable and slowly degrades over time. 
The degradation rate is greatly increased at higher temperatures (25-37 ˚C) and in an aqueous 
solution, the loss affects the antibiotic activity significantly enough that it is recommended 
cefepime not be used for clinical use in aqueous conditions at >25 ˚C for more than a few 
hours.
6
 
 
 
 
 
    I        II 
The impurity N-methyl pyrrolidine (NMP, II) may be present in cefepime samples as a result 
of degradation of the drug. NMP has been reported as having unknown toxicity by US 
Environmental Protection Agency,
7
 and the potential for toxicity to patients receiving the 
drug is yet to be determined. An experimental study performed on monkeys, in which NMP 
(50 mg/kg) was administered over 28-30 consecutive days resulted in them developing 
esotropia and ataxia.
5
 The dosage of NMP used in the study was much greater than the 
amount expected to be received in a daily dose of cefepime (~6g) administered to patients, 
but the presence of the potentially harmful impurity is still undesirable. It has been reported 
that an increase in the NMP level is proportional to the decline in the antibiotic potency of 
cefepime.
8,9
 Monitoring the level of NMP in cefepime is, therefore,  important for ensuring 
drug quality for clinical use and a threshold concentration of NMP in cefepime has been set at 
0.3 % (w/w). 
The determination of NMP in cefepime presents an analytical challenge because of the rapid 
degradation of cefepime to NMP in aqueous solution above 4 ˚C and outside the pH range 4-
NMPCefepime
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6, resulting in the presence of higher levels of NMP in solution than are present in the solid 
cefepime sample. At present, there are four main techniques employed for NMP 
determination: high performance liquid chromatography (HPLC), ion chromatography (IC), 
capillary electrophoresis (CE) and gas chromatography (GC).
5,6,8-10
 There are limitations 
associated with all these techniques. The HPLC method requires a mobile phase of pH 2 and 
the IC method uses a column temperature of 40 ˚C; both of these conditions could lead to 
degradation of cefepime and reduce measurement accuracy. Poor detection and quantification 
limits for CE and the use of a solvent with high toxicity, pyridine, to extract NMP for the GC 
technique makes these methods less desirable for routine analysis of NMP.  The preparation 
of a cefepime sample for analysis therefore requires either the extraction of the NMP from 
the cefepime matrix to minimise the contribution from NMP produced by degradation in 
solution prior to analysis, or rapid analysis of the sample solution before significant 
degradation occurs.
11
  
A further challenge in the determination of NMP in cefepime is that the singly and doubly 
protonated cefepime generated by electrospray mass spectrometry (ESI-MS) are readily 
fragmented in the intermediate pressure region of the mass spectrometer interface by 
collision-induced dissociation (CID), also known as in-source CID, to form protonated NMP. 
The NMP generated by CID interferes with response from the protonated NMP formed from 
NMP present in the cefepime sample, since NMP resulting from the sample and via CID 
cannot be distinguished by mass spectrometry alone. 
Field asymmetric waveform ion mobility spectrometry (FAIMS) is a rapid gas phase 
separation technique in which the transmission of ions is based on differences in mobility in 
low and high electric fields; a separation dimension that is highly orthogonal to m/z.
12–14
 A 
FAIMS device is therefore able to transmit ions of a selected differential mobility, in the 
similar way that a quadrupole mass analyser may be used to transmit ions of a selected m/z. 
The combination of a FAIMS device with electrospray ionization and mass spectrometry 
(ESI-FAIMS-MS) has been shown to improve selectivity and limits of 
detection/quantification without loss of linear dynamic range.
15-18
 
Miniaturised chip-based FAIMS-MS has been used for a range of pharmaceutical 
applications, including the separation of pharmaceutical excipients
17
 and isobaric potentially 
genotoxic impurities,
18 
and the reduction of chemical noise in the analysis of biofluids.
16-17
 In 
this paper, the potential for combining a miniaturised FAIMS device with direct infusion-
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ESI-MS to remove interference from NMP fragment ions generated by CID in the mass 
spectrometer interface is demonstrated, enabling the determination of NMP in cefepime. 
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2. Materials and Methods 
2.1 Chemicals 
HPLC grade methanol, water and formic acid were obtained from Fisher Scientific 
(Loughborough, UK). Cefepime was obtained from Orchid Chemicals and Pharmaceuticals 
Limited (Chennai, India). N-methyl pyrrolidine was supplied by Sigma-Aldrich Limited 
(Gillingham, UK). 
2.2 Sample Preparation 
NMP standards 
A stock solution of NMP (1 mg/ml) was prepared in methanol/water (50:50). The stock was 
subsequently diluted to 1 μg/ml with methanol/water (50:50) + 0.1% formic acid. A series of 
dilutions in the range 0.01 – 1.0 μg/ml (2-fold at each step) were used for standard addition 
experiments. 
Cefepime samples 
Fresh solutions of cefepime (5 mg/ml) were prepared in methanol 10 minutes prior to 
analysis. A single 100-fold dilution of the cefepime solution (to 50 μg/ml, 10μl) in 
methanol/water (50:50) + 0.1% formic acid (990 μl), or NMP solution (500 μl + 490 μl 
diluent) for the standard additions calibration, was performed immediately before analysis. 
NMP and methanol/water (50:50) + 0.1% formic acid solutions were combined before 
preparation of cefepime samples so that weighing and dissolving cefepime, and transferring  
an aliquot of cefepime solution (10 μl) to the diluted NMP solution were the only steps 
performed between acquisitions. 
2.3 Instrumentation 
Sample solutions and standards were infused (15 μl/min) using a syringe pump into the 
JetStream ESI source of an Agilent 6230 TOF MS (Agilent Technologies, UK) operated in 
positive ion mode. The ESI source was operated with a grounded nebuliser pressure of 35 
psig, a nozzle voltage of 2000 V, a sheath gas temperature of 250 ˚C at a flow of, 8 L/min, a 
drying gas temperature of 150 ˚C at a flow of 7 L/min and a spray shield voltage of 2500 V.  
A prototype chip-based FAIMS device (Owlstone Ltd., Cambridge, UK) was fitted at the 
inlet to the mass spectrometer (Figure 1), behind the spray shield and in front of the MS inlet 
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transfer capillary, which was operated at 3000 V with a nebulizer voltage of 2000 V. The 
chip-based FAIMS consists of multiple parallel electrode gaps (100 μm) with a short path 
length (700 μm), allowing high field strengths (<300 Td) and short ion residence times (50-
250 μs). The fragmentor voltage applied at the TOF inlet was varied between 75 and 375 V 
(25 V steps), but set to 200 V for quantitative measurements. The MS acquisition rate was set 
to 10 scans/s for FAIMS scanning experiments and 1 scan/s for quantification using static 
FAIMS. 
Scanning FAIMS experiments were carried out in the compensation field (CF) range -2 to 5 
Td (scan speed 0.5 Td/s ) at each dispersion field (DF), which was incremented in the range  
180-230 Td in 5 Td steps to determine optimum conditions to separate NMP from cefepime. 
Static FAIMS experiments used a fixed CF (0 Td) and DF (180 Td) to pre-select NMP 
generated in the ESI ion source. Cefepime solutions were infused into the source and data 
acquired for 2 min/sample. Data were acquired using Agilent MassHunter Acquisition 
B.05.00 and processed using Agilent MassHunter Qualitative Analysis B.05.00. Microsoft 
Excel 2010 was used to produce CF plots. 
 
Figure 1. Schematic diagram of the ESI-FAIMS-TOFMS interface. 
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3. Results and Discussion 
Cefepime degrades rapidly in solution, so the time between preparing a cefepime solution for 
analysis and acquiring data for the determination of NMP can potentially influence the 
accuracy of the quantification of NMP in the original cefepime sample. Sample preparation 
and analysis time therefore needs to be minimised, making the direct infusion of the sample 
into the ESI source of a mass spectrometer a potentially rapid alternative to conventional 
approaches for NMP determination. However, the conditions used for ESI-MS may lead to 
fragmentation of cefepime ions to protonated NMP in the mass spectrometer interface, which 
will increase the NMP response. The potential of FAIMS to separate the response for NMP in 
the original cefepime sample from NMP generated by in-source CID was therefore 
investigated. 
3.1 ESI-MS of cefepime: in-source CID 
ESI-MS analysis of a cefepime solution spiked with NMP (0.1% w/w), shows the presence of 
intense doubly (m/z 241) and singly (m/z 481) protonated cefepime peaks in the spectrum, 
with a relatively weak response for protonated NMP (m/z 86; Figure 2). The voltage applied 
to a lens in the intermediate pressure region of the mass spectrometer interface affects 
transmission of ions into the mass spectrometer and can also cause collision-induced 
dissociation (CID).
15,16
 The response for NMP in Figure 2 may therefore be attributed to 
contributions from NMP in the cefepime sample and from CID of protonated cefepime in the 
Figure 2. Electrospray mass spectrum of cefepime sample with NMP spiked at 0.1% (w/w). 
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mass spectrometer interface. Optimising the lens voltage (termed the fragmentor voltage for 
the mass spectrometer used in this study) is important for the analysis because it has a 
significant impact on the analyte response.  
The effect of the fragmentor voltage on the intensity of the NMP (m/z 86) and cefepime (m/z 
481) ions was investigated to determine the extent of cefepime fragmentation by CID in the 
mass spectrometer interface. NMP and cefepime were infused separately into the ESI source 
and the fragmentor voltage varied in the range 75-375 V (Figure 3). The maximum response 
for transmission of the NMP ion was at a fragmentor voltage of 200 V (Figure 3a). However, 
infusion of a cefepime standard also resulted in a response for NMP, which increased at 
fragmentor voltages above 200 V as a result of CID in the mass spectrometer interface at all 
fragmentor voltages studied (Figure 3b). The NMP response in the cefepime sample directly 
infused into the ESI source therefore arises from a combination of the NMP  in the cefepime  
Figure 3. Selected ion responses for [NMP+H]+ (m/z 86) and [Cefepime+H]+ (m/z 481) at 
25 V increments of the fragmentor voltage (75-375 V), (a) NMP standard; and (b) Cefepime 
standard.separation of these contributions allows the direct determination of NMP.  
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sample and CID of the cefepime ion generated by ESI, preventing the direct determination of 
NMP by ESI-MS. It would be possible, in principle, to subtract the percentage contribution to 
the total NMP response from in-source CID in order to determine the NMP in cefepime, but 
3.2 Direct infusion ESI-FAIMS-MS studies 
The FAIMS dispersion field (DF) and compensation field (CF) characteristics of protonated 
cefepime and NMP were investigated to determine whether these ions could be separated on 
the basis of differences in their high field and low field mobility. Figure 4 shows the mass-
selected ion responses for cefepime (m/z 241 and 481, solid grey and dashed line) and NMP 
(m/z 86, solid black line) in the FAIMS compensation field (CF) spectrum (-1.5 – 2 Td) of a 
solution of cefepime containing 0.1 % (w/w) NMP. A DF stepping experiment was used to 
determine the optimum DF (180 Td) for the separation of NMP and cefepime. The protonated 
NMP selected ion response shows two peaks at CF 0 Td and at CF 0.7 Td. The first peak (CF 
Figure 4. CF spectra showing selected ion response (SIR) of [NMP+H]+ (m/z 86) and 
[Cefepime+H]+ (m/z 481) at a 1:1000 ratio (w/w) at DF 180 
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0 Td, Figure 4 insert) matches the CF spectrum of an NMP standard (data not shown) 
indicating that this peak arises from NMP in the solution subjected to the ESI. The second 
Td.peak, centred at CF 0.7 Td, peak is associated with NMP formed by CID of the singly and 
doubly protonated cefepime in the mass spectrometer interface after transmission of the intact 
cefepime ions through the FAIMS, which therefore appears in the FAIMS spectrum at the 
same CF as cefepime. There was no evidence of significant fragmentation of the cefepime 
within the FAIMS device. Separation of NMP (0 Td) and cefepime (0.7 Td) with NMP at 
0.1% (w/w) demonstrates the effectiveness of FAIMS to transmit NMP in the presence of a 
1000 fold excess of cefepime.  
The mass spectrum extracted from the FAIMS CF scan at a CF of 0 Td shows the protonated 
NMP to be the base peak in the mass spectrum (Figure 5). There is a weak response from the 
protonated cefepime at this CF, because of the 1000 fold excess of the drug, but this is small 
compared to the relative responses for NMP and cefepime in the absence of a FAIMS 
separation. Figure 5 shows no response for the doubly protonated cefepime. The FAIMS 
device is therefore able to transmit the NMP generated in the ESI source from the original 
cefepime solution selectively, with no contribution from the NMP formed by in-source CID, 
making it possible to determine NMP in cefepime by direct ESI-FAIMS-MS without prior 
chromatographic separation.  
Figure 5. Mass spectrum of an infused sample of Cefepime spiked with NMP at 0.1% (w/w) 
obtained by ESI-FAIMS-MS (DF 180 Td; CF 0 Td). 
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The FAIMS was operated in static mode (CF 0.1 Td, DF 180 Td) to selectively transmit NMP 
generated in the ESI ion source through the device for the determination of NMP in cefepime. 
Cefepime solutions were infused into the source 10 minutes after preparation to avoid 
degradation in solution and data acquired with an analysis time of 2 min/sample from the 
start of the infusion. The limit of detection for NMP was estimated to be 0.11 mg/g in the 
cefepime sample, giving a limit of quantitation 0.36 mg/g, which is equivalent to 0.036%, 
well below the 0.3% threshold concentration for NMP in cefepime. The %RSD for replicate 
samples was 3.85% (n=6, 0.37 μg/ml) for NMP, with good linearity (R2 0.9979) for standard 
additions in the range 0.005 – 0.5 μg/ml. These preliminary quantitative data demonstrate the 
potential of direct ESI-FAIMS-MS for the determination of NMP in cefepime at, and below, 
the threshold concentration, subject to full validation of the method. 
 
4. Conclusions 
The formation of NMP by solution degradation and CID of cefepime in the intermediate 
pressure region of the mass spectrometer interface presents an analytical challenge for the 
determination of NMP in cefepime. The use of a FAIMS separation of NMP and cefepime 
ions prior to mass spectrometric analysis allows NMP in a cefepime sample to be 
distinguished from NMP ions generated by CID in the mass spectrometer interface. Direct 
infusion of a cefepime solution using ESI-FAIMS-MS is shown to be a rapid, selective 
method for the quantitative determination of NMP in cefepime with an LOQ well below the 
required 0.3 % threshold and good precision. The approach reported here for NMP in 
cefepime has potential for generic application to the direct determination of impurities 
present in other active pharmaceutical ingredients which fragment to yield the impurity ion 
by CID.  
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